• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
  • Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
ISPOR 2025: Characteristics and adherence of patients initiating injectable cabotegravir for HIV treatment or prevention 

ISPOR 2025: Characteristics and adherence of patients initiating injectable cabotegravir for HIV treatment or prevention 

by Truveta Research | May 14, 2025 | Research, Research Insights

Authors: Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD, PhD ⊕Truveta, Inc, Bellevue, WA Moderate adherence was observed for...
Ending the HIV epidemic: Finding new insights with EHR data

Ending the HIV epidemic: Finding new insights with EHR data

by Truveta staff | Apr 18, 2024 | Data

In 2019, the US government unveiled the ambitious Ending the HIV Epidemic (EHE) plan, aiming to slash new HIV infections by 90% by 2030. Thanks to advances in antiretroviral therapy (ART), proven models of prevention, and data access, new HIV infections declined 12%...
Real-world prescribing of long-acting injectable cabotegravir for treatment of HIV in the United States

Real-world prescribing of long-acting injectable cabotegravir for treatment of HIV in the United States

by Truveta Research | Nov 10, 2023 | Research, Research Insights

Adequate treatments are a crucial piece in the fight against the spread of HIV, because they can make HIV viral load undetectable in the blood and thus untransmittable. Approved by the US Food and Drug Administration (FDA) in January 2021, one of the newest treatments...

Share this


Recent posts

  • Prostate cancer is in the headlines — and early detection has never been more important
  • How Truveta benchmarks AI model quality for clinical concept extraction
  • Truveta Data analysis shows improved outcomes with Impella support in high-risk heart procedures

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice